SAN DIEGO, March 14, 2023 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today...
SAN DIEGO, April 8, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for the clearance of human papillomavirus and related pre-cancerous cervical lesions, today...
SAN DIEGO, March 28, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for clearing human papillomavirus-driven pre-cancerous cervical lesions, today announced that...
— PRTX007 exhibits activation of the innate immune system in both cellular and murine animal models against respiratory syncytial virus (RSV) — — Findings demonstrate broad-spectrum antiviral activity and suitability of PRTX007 as a clinical candidate to support...
SAN DIEGO, March 10, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...
SAN DIEGO, February 24, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...